Skip to main content

Ziftomenib Maintenance After Transplant

Ziftomenib Maintenance Post Allo-HCT

  • RegistryNCT06440135
  • PhasePhase 1
  • StatusRecruiting
  • ConditionNPM1-Mutated AML in Remission After Allogeneic Transplant
  • SponsorMassachusetts General Hospital
How Ziftomenib Maintenance worksNCT064401351 min

What the film says

Read the transcript

This trial is for adults with acute myeloid leukemia with an NPM1 mutation who are in remission after a donor stem cell transplant.

The idea: after the transplant, patients take ziftomenib, a pill once a day, as maintenance. Ziftomenib targets interactions inside the leukemia cells that drive this type of AML. The hope is that it improves outcomes after transplant.

The study looks at safety, effects, and the recommended dose.

This phase 1 study plans 22 patients. At Massachusetts General Hospital in Boston, Zachariah DeFilipp leads it.

Public record; not medical advice.

Sources behind this film

  • ClinicalTrials.gov record NCT06440135

    Adults; NPM1 AML in remission; after allo-HCT; Ziftomenib oral once daily; Targets interactions; improve outcomes; Safety, effects, recommended dose (+1 more lines)

The drug

What is being tested.

This is a prospective, multi-center, open-label, phase I study of ziftomenib as maintenance therapy following allogeneic hematopoietic cell transplantation (HCT). This study is testing whether ziftomenib, combined with the standard allo-HCT treatment, is safe and effective in treating blood cancer. This study will test if ziftomenib improves outcomes after allo-HCT. The study drug is given after the allo-HCT, in combination with standard treatment and aftercare.

This study consists of 2 parts: Part A (Dose Escalation): The investigators are looking to find the highest dose of the study intervention that can be administered safely without severe or unmanageable side effects, not everyone who participates in this research study will receive the same dose of the study intervention. The dose given will depend on the number of participants who have been enrolled prior and how well the dose was tolerated.

The study

How the trial runs.

The purpose of this study is to test the safety, effects, and recommended dose of an investigational drug, ziftomenib, in addition to the standard treatment on blood cancer with Allogeneic Hematopoietic Cell Transplantation (allo-HCT). This study plans to learn more about ziftomenib, which targets and inhibits negative interactions within cancer cells related to AML, when given after allo-HCT, to determine if it improves outcomes following allo-HCT.

The name of the study drug involved in this study is: • Ziftomenib

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Pathologically confirmed diagnosis of acute myeloid leukemia (AML).
  • Complete remission (CR) or complete remission with incomplete count recovery (CRi) at screening.
  • no circulating blasts in peripheral blood and <5% blasts in bone marrow
  • no extramedullary disease
  • platelet count ≥100 x 10(9)/L and/or absolute neutrophil count ≥1000/µL

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.